Pressurized metered dose inhalers (MDIs), dry powder inhalers (DPIs), and nebulizers are used in pulmonary drug delivery. The route is used for the treatment of diabetes, lung cancer, and migraine.
The global pulmonary drug delivery systems market is estimated to account for US$ 30,005.80 Mn in terms of value in 2020 and is expected to reach US$ 41,072.7 Mn by the end of 2027.
Global Pulmonary Drug Delivery Systems Market: Drivers
R&D in use of inhalers is expected to propel growth of the global pulmonary drug delivery systems market over the forecast period. For instance, in September 2018, researchers from University of Helsinki, Finland, reported investigation of non-verbal, demonstrational videos as a method of teaching inhaler naïve individuals how to use a dry powder inhaler (DPI).
Global Pulmonary Drug Delivery Systems Market: Opportunities
Adoption of mesoporous silica particles is expected to offer lucrative growth opportunities for players in the global pulmonary drug delivery systems market. For instance, in April 2019, researchers from Åbo Akademi University, Finland, reported that mesoporous silica particles are viable drug carriers for pulmonary delivery of corticosteroids in the anti-inflammatory treatment of chemical-induced lung injury.
Global Pulmonary Drug Delivery Systems Market: Restraints
Product recalls are expected to hinder growth of the market. For instance, in August 2018, Sanrai International LLC initiated the recall of Sunset Compressor Nebulizer, as the product was designed for 120V usage and was being used in South Africa with 220V.
The global pulmonary drug delivery systems market was valued at US$ 28,700.0 Mn in 2019 and is forecast to reach a value of US$ 41,072.7 Mn by 2027 at a CAGR of 4.6% between 2020 and 2027. Major factor driving the growth of global pulmonary drug delivery systems market during the forecast period include product launches, and technological advancement.
MDIs held dominant position in the global pulmonary drug delivery systems market in 2019, accounting for 53.9% share in terms of value, followed by DPIs and nebulizers, respectively. In April 2016, AstraZeneca received approval for Bevespi Aerosphere, the first product using AstraZeneca’s Co-Suspension Technology. The technology enables over one medicine delivery from a single MDI.
The market is witnessing launch of digital inhalers. For instance, in January 2019, FindAir, a European company developing digital systems for asthma and COPD control, launched its commercial smart inhaler device FindAir ONE.
Major players in the market are focused on approval and launch of new devices to expand their product portfolio. For instance, in September 2019, Novartis International AG’s Concept1 inhaler received certification under the new EU Medical Devices Regulation (MDR).
Global Pulmonary Drug Delivery Systems Market: Competitive Landscape
Major players operating in the global pulmonary drug delivery systems market include, 3M Health Care, Allied Healthcare Products, Inc., AstraZeneca plc, Boehringer Ingelheim, CareFusion Corporation, GF Health Products, Inc., GlaxoSmithKline plc, Merck & Co., Inc., Novartis AG, Omron Healthcare, Inc., Glenmark Pharmaceuticals, PARI Respiratory Equipment, Inc., and Philips Healthcare.
Global Pulmonary Drug Delivery Systems Market: Key Developments
May 2020: Glenmark Pharmaceuticals Ltd. launched a Single Inhaler Triple Therapy AIRZ-FF - a combination of two bronchodilators, Glycopyrronium & Formoterol and the inhalation corticosteroid Fluticasone propionate, for the treatment of COPD
May 2020: PARI Respiratory Equipment, Inc. announced the use of its LC Sprint Reusable Nebulizer in two phase 2 clinical trials for COVID-19 using Pulmotect’s PUL-042, an inhaled immunomodulatory agent to prevent and treat coronavirus infections